Friday, May 15, 2020 – 8:00amEDT Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy […]
In this month’s Catabasis Connection, they discuss: Learning in their Phase 3 PolarisDMD trial Boys with Duchenne demonstrate capsule swallowing abilities The expected patient population Safety data on edasalonexent.
— The Interim data from EPYDIS Phase 3 trial shows that the trial is NOT FUTILE and the Independent Data Monitoring Committee recommends trial continuation — — Blinded re-estimation of […]
Italfarmaco’s EPIDYS clinical trial for Givinostat is enrolling boys age 6 and up at 40 sites around the world. See the details in Italfarmaco’s Winter 2020 community newsletter. Or join […]
Mallinckrodt Comments on its BRAVE study (A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Subjects 4 […]
View Santhera’s Duchenne Community Letter
CAMBRIDGE, Mass.–(BUSINESS WIRE)–The collaborative Trajectory Analysis Project (cTAP), a multi-stakeholder, global coalition in Duchenne muscular dystrophy (DMD), publishes research in the journal PLOS ONE providing quantitative insights to assist the […]
View the Santhera Fall Update HERE.
View the Italfarmaco Fall Newsletter HERE.
